Skip to content
Research/Immune Modulation/Daratumumab

Daratumumab

Daratumumab is a monoclonal antibody targeting CD38, a protein highly expressed on the surface of multiple myeloma cells. It works by inducing cell death through immune-mediated mechanisms and direct apoptosis, making it a valuable treatment in oncology. Its relevance to longevity and health optimization lies in its potential to modulate the immune system and target cancerous cells, although its primary use is currently in cancer therapy.

Intelligence Profile

Science

Daratumumab is a monoclonal antibody that targets the CD38 protein, which is a cell surface antigen found in high numbers on multiple myeloma cells. By binding to CD38, daratumumab induces cell death through several mechanisms:

  1. Complement-Dependent Cytotoxicity (CDC): Daratumumab activates the complement system, a part of the immune system, leading to the formation of the membrane attack complex that lyses the myeloma cells.

  2. Antibody-Dependent Cellular Cytotoxicity (ADCC): The binding of daratumumab to CD38 attracts immune effector cells, like natural killer (NK) cells, which then attack and kill the cancerous cells.

  3. Antibody-Dependent Cellular Phagocytosis (ADCP): The binding also promotes recognition and engulfment of myeloma cells by phagocytes, like macrophages.

  4. Direct Apoptosis: Daratumumab may directly induce apoptosis, or programmed cell death, in myeloma cells via cross-linking and aggregation of CD38.

These actions help reduce the number of cancer cells in the body, contributing to the management of multiple myeloma and other related conditions.

For more specific inquiries or health guidance, please consult a healthcare professional.